TABLE 2.

Summary of the survival efficacy induced by P. vivax CSP plus TRAP with vaccination regimens using vvTRAP, protein, or Rv21 in mice challenged by P. berghei sporozoites^a

Vaccine regimenb	No. of protected mice/total no. of mice	Sterile protection (%)	Median survival (days)	Survival limit (days)	Mean survival ± SD (days)	SE
Naive	0/6	0	6.78	6.49–7.08	6.78 ± 0.28	0.12
vvTRAP	0/6	0	7.28	6.46–7.62	7.12 ± 2.5	0.21
Rv21	3/6	50	13.69	6.06–20.98	13.52 ± 7.1	2.9
Rv21+vvTRAP	6/6	100	20	20.0–20.0	20.0 ± 0	0
vvTRAP+MM	0/6	0	6.89	6.52–7.53	7.03 ± 0.48	0.20
Rv21+MM	6/6	100	20	20.0–20.0	20.0 ± 0	0
Rv21+vvTRAP+MM	6/6	100	20	20.0–20.0	20.0 ± 0	0
pCS+MM	3/6	33	8.36	5.44–18.51	11.98 ± 6.23	2.54
vvTRAP+pCS+MM	0/6	0	7.64	7.02–8.35	7.68 ± 0.53	0.24
vvTRAP+Add	0/6	0	6.81	6.41–7.46	6.9 ± 0.5	0.20
Rv21+Add	5/6	83.3	20	12.7–23.2	20.0 ± 0	2.03
Rv21+vvTRAP+Add	6/6	100	20	20.0–20.0	20.0 ± 0	0

^aVaccinated BALB/c mice were challenged with 2,000 sporozoites of the PvCSP-PvTRAP 2207 cl1 strain, as described in the legend of Fig. 4.

^bAdjuvants used were Matrix-M (MM) and AddaVax (Add).